>
网站首页期刊介绍通知公告编 委 会投稿须知电子期刊广告合作联系我们
最新消息:
肿瘤微环境中的树突状细胞及其在肿瘤治疗中的作用
作者:蔡枫  何贞月  姜婷婷  张伟云 
单位:南京大学 医学院, 江苏省分子医学重点实验室, 江苏 南京 210093
关键词:肿瘤微环境 树突状细胞 JAK2/STAT3信号通路 炎症介质 DC疫苗 文献综述 
分类号:R73-36; R730.5
出版年·卷·期(页码):2012·31·第二期(225-229)
摘要:

树突状细胞(DC)是目前发现的功能最强大的专职抗原递呈细胞,既能起始又能够激活抗原特异性初始T细胞应答,在机体免疫系统中发挥着重要作用。近年来,关于DC在肿瘤免疫中的作用引起了研究者的关注。在此篇综述中,我们重点关注了肿瘤微环境中DC与信号转导和活化转录因子3信号通路激活及炎症介导因子之间的相互关系,以及DC在肿瘤治疗中的作用。

参考文献:

[1] MANTOVANI A,ALLAVENA P,SICA A,et al.Cancer-related inflammation[J].Nature,2008,454(24):436-444.
[2] NOVITSKIY S V,RYZHOV S,ZAYNAGETDINOV R,et al.Adenosine receptors in regulation of dendritic cell differentiation and function[J].Blood,2008,112(5):1822-1831.
[3] NAM E H,PARK S,KIM P H.TGF-β1 induces mouse dendritic cells to express VEGF and its receptor (Flt-1) under hypoxic conditions[J].Exp Mol Med,2010,42(9): 606-613.
[4] Von BERGWELT-BAILDON M S,POPOV A,SARIC T,et al.CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo:additional mechanisms of T-cell inhibition[J].Blood,2006,108:228-237.
[5] BETTS B C,St ANGELO ET,KENNEDY M,et al.Anti-IL-6 receptor alpha (tocilizumab) does not inhibit human monocyte-derived dendritic cell maturation or alloreactive T-cell responses[J]. Blood,2011,118(19):5340-5343.
[6] ONISHI Y,FEHERVARI Z,YAMAGUCHI T,et al.Foxp3+natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation[J].Proc Nat Acad Sci USA,2008,105(29):10113-10118.
[7] WING K,ONISHI Y,PRIETO-MARTIN P,et al.CTLA-4 control over Foxp3+regulatory T cell function[J].Science,2008,322(5899):271-275.
[8] BAYRY J,TRIEBEL F,KAVERI S V,et al.Human dendritic cells acquire a semi-mature phenotype and lymph node homing potential through interaction with CD4+CD25+regulatory T cells[J].J Immunol,2007,178(7):4184-4193.
[9] BENEKLI M,XIA Z,DONOHUE K A,et al.Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease-free survival[J].Blood,2002,99(1):252-257.
[10] SHAH N G,TRIVEDI T I,TANKSHALI R A,et al.Stat3 expression in oral squamous cell carcinoma: association with clinico-pathological parameters and survival[J].Int J Biol Mark,2006,21(3):175-183.
[11] NEFEDOVA Y,GABRILOVICH D I.Targeting of Jak/STAT pathway in antigen presenting cells in cancer[J].Curr Cancer Drug Targets,2007,7(1):71-77.
[12] NEFEDOVA Y,HUANG M,KUSMARTSEV S,et al.Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer[J].J Immunol,2004,172(1):464-474.
[13] WANG T,NIU G,KORTYLEWSKI M,et al.Regulation of the innate and adaptive immune responses by STAT3 signaling in tumor cells[J].Nat Med,2004,10(1):48-54.
[14] FLETCHER S,DREWRY J A,SHAHANI V M,et al.Molecular disruption of oncogenic signal transducer and activator of transcription 3 (STAT3) protein[J].Biochem Cell Biol,2009,87(6):825-833.
[15] FUJITANI Y,HIBI M,FUKADA T,et al.An alternative pathway for STAT activation that is mediated by the direct interaction between JAK and STAT[J].Oncogene,1997,14(7):751-761.
[16] LIN A,SCHILDKNECHT A,NGUYEN L T,et al.Dendritic cells integrate signals from the tumor microenvironment to modulate immunity and tumor growth[J].Immunol Lett,2010,127(2):77-84.
[17] Van CRUIJSEN H,OOSTERHOFF D,LINDENBERG J J,et al.Glioblastoma-induced inhibition of Langerhans cell differentiation from CD34(+) precursors is mediated by IL-6 but unaffected by JAK2/STAT3 inhibition[J].Immunotherapy,2011,3(9):1051-1061.
[18] MOLAVI O,MA Z S,HAMDY S,et al.Synergistic antitumor effects of CpG oligodeoxynucleotide and STAT3 inhibitory agent JSI-124 in a mouse melanoma tumor model[J].Immunol Cell Biol,2008,86(6):506-514.
[19] EPHREM A,CHAMAT S,MIQUEL C,et al.Expansion of CD4+CD25+regulatory T cells by intravenous imunoglobulin: a critical factor in controlling experirnental autoimmune encephalomyelitis[J].B1ood,2008,111(2):715-722.
[20] YU J H,KIM K H,KIM H.SOCS 3 and PPAR-γ ligands inhibit the expression of IL-6 and TGF-β1 by regulating JAK2/STAT3 signaling in pancreas[J].Int J Biochem Cell Biol,2007,10(1):1-12.
[21] BROMBERG J F,WRZESZCZYNSKA M H,DEVGAN G,et al.Stat3 as an oncogene[J].Cell,1999,98(3):295-303.
[22] DUNN G P,BRUCE A T,SHEEHAN K C,et al.A critical function for type Ⅰ interferons in cancer immunoediting[J].Nat Immunol,2005,6(7):722-729.
[23] GALON J,COSTES A,SANCHEZ-CABO F,et al.Type,density,and location of immune cells within human colorectal tumors predict clinical outcome[J].Science,2006,313(5795):1960-1964.
[24] LIU J,XIANG Z,MA X.Role of IFN regulatory factor-1 and IL-12 in immunological resistance to pathogenesis of N-methyl-N-nitrosourea-induced T lymphoma[J].J Immunol,2004,173(2):1184-1193.
[25] SHANKARAN V,IKEDA H,BRUCE A T,et al.IFN gamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity[J].Nature,2001,410(6832):1107-1111.
[26] Van den BROEK M E,KAGI D,OSSENDORP F,et al.Decreased tumor surveillance in perforin-deficient mice[J].J Exp Med,1996,184(5):1781-1790.
[27] ZHANG L,CONEJO-GARCIA J R,KATSAROS D,et al.Intratumoral T cells,recurrence,and survival in epithelial ovarian cancer[J].N Engl J Med,2003,348(3):203-213.
[28] LADANYI A,KISS J,SOMLAI B,et al.Density of DC-LAMP(+) mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor[J].Cancer Immunol Immunother,2007,56(9):1459-1469.
[29] APETOH L,LOCHER C,GHIRINGHELLI F,et al.Harnessing dendritic cells in cancer[J].Semin Immunol,2011,23(1):42-49.
[30] IWAMOTO M,SHINOHARA H,MIYAMOTO A,et al.Prognostic value of tumor-infiltrating dendritic cells expressing CD83 in human breast carcinomas[J].Int J Cancer,2003,104(1):92-97.
[31] TSUKAYAMA S,OMURA K,YOSHIDA K,et al.Prognostic value of CD83-positive mature dendritic cells and their relationto vascular endothelial growth factor in advanced human gastric cancer[J].Oncol Rep,2005,14(2):369-375.
[32] KOBUKAI S,KREMERS G J,COBB J G,et al.Induction of anti-tumor immunity by dendritic cells loaded with membrane-translocating mucin 1 peptide antigen[J].Translational Oncology,2011,4 (1):1-8.
[33] VIAUD S,THRY C, PLOIX S,et al.Dendritic cell-derived exosomes for cancer immunotherapy: what's next?[J].Cancer Res,2011,70(4):1281-1285.
[34] PALUCKA K,UENO H,FAY J,et al.Dendritic cells and immunity against cancer[J].J Int Med,2011,269(1):64-73.
[35] PEGGS K S,QUEZADA S A,CHAMBERS C A,et al.Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies[J].J Exp Med,2009,206:1717-1725.
[36] PILON-THOMAS S,MACKAY A,VOHRA N,et al.Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma[J].J Immunol,2010,184:3442-3449.
[37] CURRAN M A,MONTALVOW,YAGITA H,et al.PD-1and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors[J].Proc Natl Acad Sci USA,2010,107:4275-4280.
[38] 高佩芳,姚茹冰,蔡辉,等.树突状细胞在类风湿关节炎免疫耐受治疗中的作用[J].现代医学,2009,37(4):316-318.
[39] 林琳,沈洪,王立新,等.黄芪甲苷、β-榄香烯对小鼠树突状细胞免疫功能的影响[J].东南大学学报:医学版,2011,30(2):294-297.

服务与反馈:
文章下载】【发表评论】【查看评论】【加入收藏
提示:您还未登录,请登录!点此登录
您是第 405524 位访问者


copyright ©《东南大学学报(医学版)》编辑部
联系电话:025-83272481 83272483
电子邮件:
bjb@pub.seu.edu.cn

苏ICP备09058364